{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:53:26Z","timestamp":1792407206955,"version":"4.4.0"},"reference-count":141,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular disease is the leading cause of death worldwide, and its prevalence is increasing due to the aging of societies. Atherosclerosis, a type of chronic inflammatory disease that occurs in arteries, is considered to be the main cause of cardiovascular diseases such as ischemic heart disease or stroke. In addition, the inflammatory response caused by atherosclerosis confers a significant effect on chronic inflammatory diseases such as psoriasis and rheumatic arthritis. Here, we review the mechanism of action of the main causes of atherosclerosis such as plasma LDL level and inflammation; furthermore, we review the recent findings on the preclinical and clinical effects of antibodies that reduce the LDL level and those that neutralize the cytokines involved in inflammation. The apolipoprotein B autoantibody and anti-PCSK9 antibody reduced the level of LDL and plaques in animal studies, but failed to significantly reduce carotid inflammation plaques in clinical trials. The monoclonal antibodies against PCSK9 (alirocumab, evolocumab), which are used as a treatment for hyperlipidemia, lowered cholesterol levels and the incidence of cardiovascular diseases. Antibodies that neutralize inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6, IL-17, and IL-12\/23) have shown promising but contradictory results and thus warrant further research.<\/jats:p>","DOI":"10.3390\/ijms22115770","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:33:20Z","timestamp":1622201600000},"page":"5770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases"],"prefix":"10.3390","volume":"22","author":[{"given":"Eunhye","family":"Ji","sequence":"first","affiliation":[{"name":"Division of Cardiology, Heart Institute, Asan Medical Center, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-7948","authenticated-orcid":false,"given":"Sahmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Heart Institute, Asan Medical Center, Seoul 05505, Korea"},{"name":"Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Otreba, M., Kosmider, L., and Rzepecka-Stojko, A. (2021). Polyphenols\u2019 Cardioprotective Potential: Review of Rat Fibroblasts as Well as Rat and Human Cardiomyocyte Cell Lines Research. Molecules, 26.","DOI":"10.3390\/molecules26040774"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2021.01.005","article-title":"Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis","volume":"170","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_3","first-page":"E176","article-title":"Myocardial Infarction-From Atherosclerosis to Thrombosis Uncovering New Diagnostic and Therapeutic Approaches","volume":"39","author":"Palasubramaniam","year":"2019","journal-title":"Arter. Throm. Vas."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists Collaborators, Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., Voysey, M., Gray, A., and Collins, R. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet, 380, 581\u2013590.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wu, M.-Y., Li, C.-J., Hou, M.-F., and Chu, P.-Y. (2017). New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102034"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.12688\/f1000research.18901.1","article-title":"Inflammation in atherosclerotic cardiovascular disease","volume":"8","author":"Shah","year":"2019","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154461","DOI":"10.1016\/j.metabol.2020.154461","article-title":"Advances in biological therapies for dyslipidemias and atherosclerosis","volume":"116","author":"Valanti","year":"2021","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Gistera","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1073\/pnas.76.1.333","article-title":"Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition","volume":"76","author":"Goldstein","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","first-page":"136","article-title":"CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima","volume":"119","author":"Park","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/nm.3258","article-title":"Local proliferation dominates lesional macrophage accumulation in atherosclerosis","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Libby, P. (2021). Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. Cells, 10.","DOI":"10.3390\/cells10040951"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.1990440","article-title":"Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis","volume":"251","author":"Cybulsky","year":"1991","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.110.207415","article-title":"Recent advances on the role of cytokines in atherosclerosis","volume":"31","author":"Taleb","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tips.2019.02.004","article-title":"Targeting Mechanosensitive Transcription Factors in Atherosclerosis","volume":"40","author":"Niu","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in Antibody Design","volume":"17","author":"Tiller","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: Successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid Intima-Media Thickness in Psoriatic Arthritis","volume":"31","author":"Iervolino","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Langley, R.G., Papp, K., Gottlieb, A.B., Krueger, G.G., Gordon, K.B., Williams, D., Valdes, J., Setze, C., and Strober, B. (2012). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Derm. Venereol.","DOI":"10.1111\/j.1468-3083.2012.04705.x"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/01.ATV.0000067935.02679.B0","article-title":"Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease","volume":"23","author":"Fredrikson","year":"2003","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.atherosclerosis.2008.11.020","article-title":"Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions","volume":"205","author":"Nitulescu","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2007.07.081","article-title":"Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1\u2212\/\u2212\/Low-Density Lipoprotein Receptor\u2212\/\u2212Mice","volume":"50","author":"Schiopu","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08916930500050525","article-title":"Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression","volume":"38","author":"Fredrikson","year":"2005","journal-title":"Autoimmunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molmet.2013.06.001","article-title":"Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques","volume":"2","author":"Li","year":"2013","journal-title":"Mol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/ATVBAHA.115.306938","article-title":"Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events","volume":"36","author":"Alm","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.116.012677","article-title":"Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes","volume":"47","author":"Asciutto","year":"2016","journal-title":"Stroke"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcmg.2014.06.021","article-title":"FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity","volume":"8","author":"Singh","year":"2015","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1038\/s41598-021-88430-1","article-title":"Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-\/- mice","volume":"11","author":"Mattisson","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12933-020-01009-4","article-title":"Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes","volume":"19","author":"Tang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2019.07.023","article-title":"Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease","volume":"289","author":"Morelli","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: A convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","article-title":"New Pharmacological Approaches to Target PCSK9","volume":"22","author":"Catapano","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metabolism"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2005.01.051","article-title":"A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis","volume":"45","author":"Chen","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2009.06.023","article-title":"Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles","volume":"208","author":"Norata","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","author":"Brandts","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/CIRCRESAHA.112.275859","article-title":"Antibodies to PCSK9","volume":"111","author":"Maxwell","year":"2012","journal-title":"Circ. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.02.002","article-title":"Evolving targets for the treatment of atherosclerosis","volume":"187","author":"Solanki","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: A new lipid-lowering therapy","volume":"878","author":"Daum","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14797\/mdcj-15-1-32","article-title":"Poststatin Lipid Therapeutics: A Review","volume":"15","author":"Jia","year":"2019","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.acmx.2016.11.013","article-title":"PCSK9 inhibitors in the current management of atherosclerosis","volume":"87","author":"Whayne","year":"2017","journal-title":"Arch. Cardiol. M\u00e9xico"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil\u2013lymphocyte ratio and incident atherosclerotic events: Analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","article-title":"PCSK9 signaling pathways and their potential importance in clinical practice","volume":"8","author":"Malinowski","year":"2017","journal-title":"EPMA J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-019-0784-8","article-title":"The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know","volume":"21","author":"Jia","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fcvm.2019.00014","article-title":"Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials","volume":"6","author":"Wong","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: A narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.07.007","article-title":"Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities","volume":"276","author":"Khambhati","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0008-6363(96)00145-9","article-title":"Synthesis of TNF\u03b1 and TGF\u03b2 mRNA in the different micro-environments within atheromatous plaques","volume":"32","author":"Rayment","year":"1996","journal-title":"Cardiovasc. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","article-title":"Elevation of Tumor Necrosis Factor-\u03b1 and Increased Risk of Recurrent Coronary Events After Myocardial Infarction","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2004.11.016","article-title":"Disruption of tumor necrosis factor-\u03b1 gene diminishes the development of atherosclerosis in ApoE-deficient mice","volume":"180","author":"Ohta","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"26174","DOI":"10.1074\/jbc.271.42.26174","article-title":"Accelerated Atherosclerosis in Mice Lacking Tumor Necrosis Factor Receptor p55","volume":"271","author":"Schreyer","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk","volume":"39","author":"Libby","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_69","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Gkalpakiotis, S., Arenbergerova, M., Gkalpakioti, P., Potockova, J., Arenberger, P., and Kraml, P. (2020). Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study. Dermatol. Ther., 33.","DOI":"10.1111\/dth.14110"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-017-0217-6","article-title":"Golimumab: A Review in Inflammatory Arthritis","volume":"31","author":"Frampton","year":"2017","journal-title":"BioDrugs"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Pelechas, E., Voulgari, P., and Drosos, A. (2019). Golimumab for Rheumatoid Arthritis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030387"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-\u03b1, in Patients With Moderate-to-Severe Heart Failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.acvd.2019.11.001","article-title":"Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases","volume":"113","author":"Libby","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fimmu.2012.00315","article-title":"IL-1 family cytokines trigger sterile inflammatory disease","volume":"3","author":"Lukens","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2018.05.010","article-title":"Critical roles of inflammation in atherosclerosis","volume":"73","author":"Moriya","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1084\/jem.182.5.1447","article-title":"The interleukin-1 beta-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy","volume":"182","author":"Singer","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 Beta as a Target for Atherosclerosis Therapy","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of Interleukin-1\u03b2 Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still\u2019s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of Interleukin-1\u03b2 Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of Interleukin-1\u03b2 and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial","volume":"76","author":"Everett","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.02.062","article-title":"All roads lead to IL-6: A central hub of cardiometabolic signaling","volume":"259","author":"Libby","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.atherosclerosis.2008.07.031","article-title":"Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)","volume":"203","author":"Saremi","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.ATV.19.10.2364","article-title":"Interleukin-6 Exacerbates Early Atherosclerosis in Mice","volume":"19","author":"Huber","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(00)00682-1","article-title":"Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17\u03b2-estradiol in apolipoprotein E-deficient mice","volume":"156","author":"Elhage","year":"2001","journal-title":"Atherosclerosis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"(2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet, 379, 1214\u20131224.","DOI":"10.1016\/S0140-6736(12)60110-X"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/annrheumdis-2015-207760","article-title":"Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Results from a European collaborative study","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_100","first-page":"310","article-title":"Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept","volume":"36","author":"Generali","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the ASSAIL-MI-trial: A randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open Heart"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jdermsci.2017.06.010","article-title":"IL-17 for therapy","volume":"87","author":"Kurschus","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell\u2013mediated intestinal inflammation","volume":"10","author":"Kamanaka","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.109.924886","article-title":"Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E\u2013Deficient Mice","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCRESAHA.111.261784","article-title":"The IL-17A\/IL-17RA Axis Plays a Proatherogenic Role via the Regulation of Aortic Myeloid Cell Recruitment","volume":"110","author":"Butcher","year":"2012","journal-title":"Circ. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/ATVBAHA.111.227629","article-title":"Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E\u2013Deficient Mice","volume":"31","author":"Madhur","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice","volume":"32","author":"Danzaki","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/CIRCRESAHA.113.301934","article-title":"Increased Atherosclerotic Lesion Formation and Vascular Leukocyte Accumulation in Renal Impairment Are Mediated by Interleukin-17A","volume":"113","author":"Ge","year":"2013","journal-title":"Circ. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_114","first-page":"196ra100","article-title":"Transforming Growth Factor\u2013\u03b2 Signaling in T Cells Promotes Stabilization of Atherosclerotic Plaques Through an Interleukin-17\u2013Dependent Pathway","volume":"5","author":"Robertson","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-014-0042-5","article-title":"Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy","volume":"4","author":"Gisondi","year":"2014","journal-title":"Dermatol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.cell.2016.11.044","article-title":"IL-17 Blockade in Psoriasis","volume":"167","author":"Burkett","year":"2016","journal-title":"Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/annrheumdis-2016-eular.2049","article-title":"Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Results Versus Adalimumab up to 48 Weeks Using a Matching-Adjusted Indirect Comparison","volume":"75","author":"Nash","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an Anti\u2013Interleukin-17\u2013Receptor Antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: A systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6145810","DOI":"10.1155\/2016\/6145810","article-title":"Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis","volume":"2016","author":"Kugyelka","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2369279","DOI":"10.1155\/2020\/2369279","article-title":"The Expression of IL-12 Family Members in Patients with Hypertension and Its Association with the Occurrence of Carotid Atherosclerosis","volume":"2020","author":"Ye","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.npep.2012.11.001","article-title":"Systemic treatment with neuropeptide Y receptor Y1-antagonist enhances atherosclerosis and stimulates IL-12 expression in ApoE deficient mice","volume":"47","author":"Kakko","year":"2013","journal-title":"Neuropeptides"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.ATV.19.3.734","article-title":"The Role of Interleukin 12 in the Development of Atherosclerosis in ApoE-Deficient Mice","volume":"19","author":"Lee","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0002-9440(10)63471-2","article-title":"The Role of Interleukin-4 and Interleukin-12 in the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice","volume":"163","author":"Davenport","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/CIRCULATIONAHA.104.533463","article-title":"Blockade of Interleukin-12 Function by Protein Vaccination Attenuates Atherosclerosis","volume":"112","author":"Hauer","year":"2005","journal-title":"Circulation"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Sun, J., Yu, H., Liu, H., Pu, D., Gao, J., Jin, X., Liu, X., and Yan, A. (2020). Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents. J. Clin. Lab. Anal., 34.","DOI":"10.1002\/jcla.23108"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ye, J., Wang, Y., Wang, Z., Liu, L., Yang, Z., Wang, M., Xu, Y., Ye, D., Zhang, J., and Lin, Y. (2020). Roles and Mechanisms of Interleukin-12 Family Members in Cardiovascular Diseases: Opportunities and Challenges. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00129"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti\u2013Interleukin-12 Antibody for Active Crohn\u2019s Disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ced.14180","article-title":"Effect of biologics targeting interleukin-23\/-17 axis on subclinical atherosclerosis: Results of a pilot study","volume":"45","author":"Marovt","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14728222.2020.1707806","article-title":"Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: Focus on lipid disorders","volume":"24","author":"Morelli","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1253\/circj.CJ-18-0442","article-title":"ANGPTL3 Inhibitors- Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism","volume":"83","author":"Geladari","year":"2019","journal-title":"Circ. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJMc2029834","article-title":"Effect of CD47 Blockade on Vascular Inflammation","volume":"384","author":"Jarr","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/CIRCRESAHA.120.315935","article-title":"CD31 as a Therapeutic Target in Atherosclerosis","volume":"126","author":"Caligiuri","year":"2020","journal-title":"Circ. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:34Z","timestamp":1760162974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":141,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115770"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115770","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}